HeartBeam Names Peter J. Fitzgerald, MD, PhD, as Chief Medical Officer

October 12, 2022 — HeartBeam, Inc., a cardiac technology company that has developed the first and only 3D-vector ECG platform for heart attack detection anytime, anywhere,  announced the appointment of Peter J. Fitzgerald, MD, PhD, as Chief Medical Officer. In addition to his world-renowned expertise in interventional cardiology, Dr. Fitzgerald is an accomplished inventor, entrepreneur, and investment fund founder. 

“We are thrilled to have Dr. Fitzgerald, one of the world’s preeminent opinion leaders in cardiology and digital health, join the HeartBeam leadership team and play a major role in defining best paths to adoption, clinical strategies, and partnerships to advance our products in the market,” said Branislav Vajdic, PhD, founder and CEO of HeartBeam. “In addition to his cardiovascular clinical and research expertise, Dr. Fitzgerald has a rich history of developing successful collaborations with partners in the industry and has developed deep connections across the investment and medical communities.”  

About Peter J. Fitzgerald, MD, PhD 

Dr. Fitzgerald is the Director of the Center for Cardiovascular Technology and Director of the Cardiovascular Core Analysis Laboratory at Stanford University Medical School. He is an interventional cardiologist and holds a PhD in electrical engineering. Dr. Fitzgerald is Professor Emeritus in the Departments of Medicine (Cardiology) at Stanford University and has led or participated in over 175 clinical trials, published over 650 manuscripts/chapters, and lectures worldwide. Over the past two decades, he has trained over 150 post-doctoral candidates in engineering and medicine. Dr. Fitzgerald has been principle and founder of 24 medical device companies in the San Francisco Bay area, transitioning 18 of these start-ups to medium/large-cap life science companies. In 2009, he co-founded TriVentures, an Israeli-based incubator/venture fund for early-stage medical technology and digital health.  He has also been a consultant to the US Food and Drug Administration for the past 20 years, focused on medical technology and data driven health analytics. 

“HeartBeam’s focus on bringing novel diagnostic tools to cardiac patients, especially those with a high risk for a heart attack, could have a significant, positive impact on medical outcomes and quality of life for patients while potentially saving healthcare dollars,” said Dr. Fitzgerald. “I look forward to supporting the planned advancement of the Company’s rich product pipeline to deliver comprehensive cardiac care for patients anytime, anywhere.” 

For more information: www.heartbeam.com